RT Journal Article
SR Electronic
T1 Transmission of SARS-CoV-2 in standardised First Few X cases and household transmission investigations: a systematic review and meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.01.22273107
DO 10.1101/2022.04.01.22273107
A1 Lewis, Hannah C
A1 Marcato, Adrian J
A1 Meagher, Niamh
A1 Valenciano, Marta
A1 Villanueva-Cabezas, Juan-Pablo
A1 Spirkoska, Violeta
A1 Fielding, James E
A1 Karahalios, Amalia
A1 Subissi, Lorenzo
A1 Nardone, Anthony
A1 Cheng, Brianna
A1 Rajatonirina, Soatiana
A1 Okeibunor, Joseph
A1 Aly, Eman A
A1 Barakat, Amal
A1 Jorgensen, Pernille
A1 Azim, Tasnim
A1 Wijesinghe, Pushpa Ranjan
A1 Le, Linh-Vi
A1 Rodriguez, Angel
A1 Vicari, Andrea
A1 Van Kerkhove, Maria
A1 McVernon, Jodie
A1 Pebody, Richard
A1 Price, David J
A1 Bergeri, Isabel
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/04/15/2022.04.01.22273107.abstract
AB We aimed to estimate the household secondary infection attack rate (hSAR) of SARS-CoV-2 in investigations aligned with the WHO Unity Studies Household Transmission Investigations (HHTI) protocol. We conducted a systematic review and meta-analysis according to PRISMA 2020 guidelines.We searched Medline, Embase, Web of Science, Scopus and medRxiv/bioRxiv for ‘Unity-aligned’ First Few X cases (FFX) and HHTIs published between 1 December 2019 and 26 July 2021. Standardised early results were shared by WHO Unity Studies collaborators (to 1 October 2021). We used a bespoke tool to assess investigation methodological quality. Values for hSAR and 95% confidence intervals (CIs) were extracted or calculated from crude data. Heterogeneity was assessed by visually inspecting overlap of CIs on forest plots and quantified in meta-analyses.Of 9988 records retrieved, 80 articles (64 from databases; 16 provided by Unity Studies collaborators) were retained in the systematic review and 62 were included in the primary meta-analysis. hSAR point estimates ranged from 2%–90% (95% prediction interval: 3%–71%; I2=99.7%); I2 values remained >99% in subgroup analyses, indicating high, unexplained heterogeneity and leading to a decision not to report pooled hSAR estimates.FFX and HHTI remain critical epidemiological tools for early and ongoing characterisation of novel infectious pathogens. The large, unexplained variance in hSAR estimates emphasises the need to further support standardisation in planning, conduct and analysis, and for clear and comprehensive reporting of FFX and HHTIs in time and place, to guide evidence-based pandemic preparedness and response efforts for SARS-CoV-2, influenza and future novel respiratory viruses.Competing Interest StatementThis work was supported by WHO through funding from the WHO Solidarity Response Fund and the German Federal Ministry of Health COVID-19 Research and Development. EAB reports serving on the Data and Safety Monitoring Board for COVID vaccine trial for AstraZeneca Biopharmaceuticals R&D (no payments, outside the submitted work). HN reports serving on the Data and Safety Monitoring Board for Oxford University ComCov studies (no payments, outside the submitted work).Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=260065 Funding StatementThis work was supported by WHO through funding from the WHO Solidarity Response Fund and the German Federal Ministry of Health COVID-19 Research and Development. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were available in peer-reviewed publications (all referenced in the document) or at: https://zenodo.org/communities/unity-sero-2021/?page=1&size=20I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript as references (peer-reviewed publications) or at: https://zenodo.org/communities/unity-sero-2021/?page=1&size=20 https://zenodo.org/communities/unity-sero-2021/?page=1&size=20